세계의 미세유체 면역측정 시장 : 제품, 기술, 용도 및 최종 사용자별 예측(-2030년)

Microfluidic Immunoassay Market by Product (Cartridge [Polymer, Glass, Silicon], Reagents, System), Technology (Electrochemical, Optical), Application (Cardiology, Oncology, Infectious Disease), and End User (Pharmaceutical, Hospital)-Global Forecast to 2030

The global microfluidic immunoassay market is expected to reach $1.47 billion by 2030 at a CAGR of 7.4% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the increasing use of microfluidic immunoassays in drug discovery & development and biomarker detection, the advantages of lab-on-chip immunoassays over conventional immunoassays, pharmaceutical & biotechnology companies' increasing focus on research & development, and the miniaturization of biological and chemical assays. However, bubble formation and dead volume in microfluidics devices restrain the growth of this market.

Moreover, the increasing demand for point-of-care diagnostics and recent advancements in microfluidic immunoassay technology are expected to generate market growth opportunities. However, the selection of suitable substrate materials for designing microfluidic chips and product design and cost-related limitations in developing countries are major challenges for market stakeholders.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020-2023). The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.).

Among all the products studied in this report, in 2023, the consumables segment is expected to account for the largest share of the microfluidic immunoassay market. The large market share of this segment is attributed to the repetitive use of kits, the growing portfolio of disease-specific kits for early diagnosis of diseases, and the increasing product approvals. The continuous advancements in reagents and kits, the development of user-friendly diagnostic kits, and the adoption of microfluidic immunoassay cartridges in clinical and research laboratories are positively impacting the demand for consumables used in microfluidics.

Among all the technologies studied in this report, the electrochemical detection segment is projected to register the highest CAGR during the forecast period. Electrochemical detection is increasingly used in the microfluidic immunoassay owing to benefits such as low cost & power requirements, low sample & reagent consumption, portability, and short response time, contributing to the highest CAGR of this segment.

Among all the applications studied in this report, in 2023, the cardiology segment is expected to account for the largest share of the microfluidic immunoassay market. The large market share of this segment is attributed to increasing applications of microfluidic cartridges in biomarker profiling of cardiovascular diseases and understanding disease mechanisms. The demand for microfluidic immunoassay is increasing in biomedical and clinical fields for research on cardiac biomarkers, contributing to the largest share of the market.

Among all the end users studied in this report, the pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to factors such as the increasing R&D investments by pharmaceutical & biotechnology companies, the widespread utilization of microfluidic immunoassay in drug discovery & development, and a growing emphasis on personalized medicine research. The rising spending on R&D by pharmaceutical companies is also contributing to the largest share of this segment.

An in-depth analysis of the geographical scenario of the global microfluidic immunoassay market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the microfluidic immunoassay market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's large share is attributed to the region's high R&D spending by the pharmaceutical & biotechnology companies for the development of drugs and biomarker identification, increasing prevalence of chronic diseases, rising healthcare expenditure, presence of leading market players in the region, and favorable government initiatives for research & development. According to the U.S. Congressional Budget Office, U.S. pharmaceutical R&D expenditure increased from USD 91.1 billion in 2020 to USD 102.3 billion in 2021.

Scope of the Report:

Microfluidic Immunoassay Market Assessment, by Product

• Consumables
• Cartridges
  • Polymer
  • Glass
  • Silicon
• Reagents
• Systems

Microfluidic Immunoassay Market Assessment, by Technology

• Electrochemical Detection
• Optical Detection

Microfluidic Immunoassay Market Assessment, by Application

• Cardiology
• Single Biomarker Detection
• Multiplexed Biomarker Detection
• Infectious Diseases
• Oncology
• Other Applications

Note: Other applications consist of pregnancy, diabetes, thyroid, kidney diseases, and drug of abuse testing

Microfluidic Immunoassay Market Assessment, by End User

• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Hospital
• Other End Users

Note: Other end users include home healthcare, self-testing, academic institutes & research centers, and forensic labs.

Microfluidic Immunoassay Market Assessment, by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe (RoE)
• Asia-Pacific (APAC)
• China
• Japan
• India
• Rest of Asia-Pacific (RoAPAC)
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Impact Analysis of Market Dynamics
    • 4.2.1.1. Increasing Use of Microfluidic Immunoassays in Drug Discovery & Development and Biomarker Detection Driving Market Growth
    • 4.2.1.2. Bubble Formation and Dead Volume Limiting the Adoption of Microfluidics Devices
    • 4.2.1.3. Increasing Demand for Point-of-Care Testing Generating Growth Opportunities for Market Players
    • 4.2.1.4. Selecting Suitable Substrate Materials to Design Microfluidic Chips to Remain a Major Challenge for Market Players
  • 4.2.2. Factor Analysis
• 4.3. Technology Trends
  • 4.3.1. Multiplexed Panel Detection
  • 4.3.2. Paper-Based Microfluidics
• 4.4. Regulatory Analysis
  • 4.4.1. North America
    • 4.4.1.1. U.S.
    • 4.4.1.2. Canada
  • 4.4.2. Europe
  • 4.4.3. Asia-Pacific
    • 4.4.3.1. China
    • 4.4.3.2. Japan
    • 4.4.3.3. India
  • 4.4.4. Latin America
  • 4.4.5. Middle East
    • 4.4.5.1. Saudi Arabia
• 4.5. Pricing Analysis
• 4.6. Porter's Five Forces Analysis
  • 4.6.1. Bargaining Power of Suppliers
  • 4.6.2. Bargaining Power of Buyers
  • 4.6.3. Threat of Substitutes
  • 4.6.4. Threat of New Entrants
  • 4.6.5. Degree of Competition

5. Microfluidic Immunoassay Market Assessment-by Product

• 5.1. Overview
• 5.2. Consumables
  • 5.2.1. Cartridges
    • 5.2.1.1. Polymer
    • 5.2.1.2. Glass
    • 5.2.1.3. Silicon
  • 5.2.2. Reagents
• 5.3. Systems

6. Microfluidic Immunoassay Market Assessment-by Technology

• 6.1. Overview
• 6.2. Electrochemical Detection
• 6.3. Optical Detection

7. Microfluidic Immunoassay Market Assessment-by Application

• 7.1. Overview
• 7.2. Cardiology
  • 7.2.1. Single Biomarker Detection
  • 7.2.2. Multiplexed Biomarker Detection
• 7.3. Infectious Diseases
• 7.4. Oncology
• 7.5. Other Applications

8. Microfluidic Immunoassay Market Assessment-by End User

• 8.1. Overview
• 8.2. Pharmaceutical & Biotechnology Companies
• 8.3. Diagnostic Laboratories
• 8.4. Hospital
• 8.5. Other End Users

9. Microfluidic Immunoassay Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. Rest of Asia-Pacific
• 9.5. Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies

11. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)

• 11.1. Abbott Laboratories
• 11.2. Revvity, Inc. (Formerly PerkinElmer, Inc.)
• 11.3. Siemens Healthineers AG.
• 11.4. QuidelOrtho Corporation.
• 11.5. Nanomix, Inc.
• 11.6. Becton, Dickinson and Company
• 11.7. Micropoint Biotechnologies Co., Ltd.
• 11.8. Biosurfit SA
• 11.9. Koninklijke Philips N.V.
• 11.10. NanoEnTek Inc.

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports